MedTrace Logo

Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer

NCT04322617 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 1200

Last updated 2024-06-04

No results posted yet for this study

Summary

This study aims to explore the efficacy of Anlotinib with or without Immune Checkpoint Inhibitor in Standard Chemo-immunotherapy Failed Advanced NSCLC.

Conditions

Interventions

DRUG

Anlotinib plus the same Immune Checkpoint Inhibitors.

Anlotinib, 8mg po qd, D1-D14 every 21days.

DRUG

Anlotinib plus the new Immune Checkpoint Inhibitors.

Anlotinib, 8mg po qd, D1-D14 every 21days.

DRUG

Anlotinib

Anlotinib, 8mg po qd, D1-D14 every 21days.

Sponsors & Collaborators

  • Hunan Province Tumor Hospital

    lead OTHER

Principal Investigators

  • Yongchang Zhang, MD · Hunan Cancer Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-03-24
Primary Completion
2028-03-24
Completion
2029-03-24

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04322617 on ClinicalTrials.gov